City Therapeutics doses first participant in CITY‑RBP4 Phase 1 trial for Stargardt disease
City Therapeutics announced that the first participant has been dosed in its first‑in‑human Phase 1 study of CITY‑RBP4, an RNA‑i therapy aimed at reducing vitamin‑A transport to the retina in Stargardt disease. The multicentre, randomised, double‑masked, placebo‑controlled trial includes healthy volunteers and patients and will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and drug activity. Initial clinical data are expected in mid‑2027.
Why it matters
The dosing marks a key development milestone that de‑risks the program and moves the company closer to potential regulatory approval, which could broaden its pipeline and affect future revenue prospects. The company expects the Phase 1 results in mid‑2027, which will determine further development pathways.
Key facts
- 1The first participant was dosed in the Phase 1 trial of CITY‑RBP4. tradingview.com
- 2The study is a randomised, double‑masked, placebo‑controlled multicentre trial involving healthy volunteers and Stargardt disease patients. tradingview.com
- 3The trial will assess safety, tolerability, pharmacokinetics, pharmacodynamics and drug activity of single and multiple subcutaneous doses. tradingview.com
- 4City Therapeutics expects to report initial clinical data in mid‑2027. tradingview.com
- 5CEO Andy Orth said the move brings the company an important step toward addressing an unmet need. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.